ZZW-115

CAS No. 801991-87-7

ZZW-115( —— )

Catalog No. M37627 CAS No. 801991-87-7

ZZW-115 is a potent NUPR1 inhibitor with a Kd of 2.1 μM and is a derivative of Trifluoperazine (TFP).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 277 In Stock
5MG 426 In Stock
10MG 630 In Stock
25MG 966 In Stock
50MG 1260 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ZZW-115
  • Note
    Research use only, not for human use.
  • Brief Description
    ZZW-115 is a potent NUPR1 inhibitor with a Kd of 2.1 μM and is a derivative of Trifluoperazine (TFP).
  • Description
    ZZW-115 is a potent NUPR1 inhibitor, with a Kd of 2.1 μM. ZZW-115 induces tumor cell death by necroptosis and apoptosis. Anticancer activity.
  • In Vitro
    ZZW-115 (0.1-33 μM; 72 hours) is efficient in killing cancer cells, with an IC50 in the range of 0.84 μM (ANOR) to 4.93 μM (HN14).ZZW-115 (0-100 μM; 24-72 hours) is efficient to kill these tumor cells with an IC50 in the range of 0.42 μM (Hep2G cells) to 7.75 μM (SaOS-2 cells).ZZW-115 induces pancreatic cell death by necrosis and apoptosis. ZZW-115 treatment induces a decrease in ATP production and induces a ROS overproduction.LDH release is significantly higher in ZZW-115-treated cells (MiaPaCa-2, 02-063, LIPC, Foie8b, and HN14 cells) than in control cells in a concentration-dependent manner. Similarly, caspase 3/7 activity is also greater in ZZW-115-treated cells. These experiments demonstrated that ZZW-115 exerted both pronecrotic and proapoptotic effects.Cell Viability Assay Cell Line:ANOR cells, MiaPaCa-2, 02-063, 01008, LIPC, 02136, HN01,01046, AOIPC, Foie8b, HN14 cells Concentration:0.1- 33 μM Incubation Time:72 hours Result:Was efficient in killing cancer cells, with an IC50 in the range of 0.84 μM (ANOR) to 4.93 μM (HN14).Cell Proliferation Assay Cell Line:U87, A375, U2OS, SaOS-2, HT29, SK-CO-1, LS174T, H1299 and H358, HepG2, PC3, THP-1, Daudi, Jurkat and MDA-MB-231 cells Concentration:0-100 μM Incubation Time:24 or 72 hours Result:Was efficient to kill these tumor cells with an IC50 in the range of 0.42 μM (Hep2G cells) to 7.75 μM (SaOS-2 cells).
  • In Vivo
    ZZW-115 (0.5-5 mg/kg; injection; daily for 30 days) inhibits the growth of pancreatic xenografted tumors.ZZW-115 (5 mg/kg for 30 days; immunocompetent C57BL/6 mice were orthotopically implanted with Panc02 cells) treatment shows the tumor size is almost unmeasurable in some cases.Animal Model:NMRI-Foxn1nu/Foxn1nu mice (nude mice) xenografted with MiaPaCa-2 cells Dosage:5, 2.5, 1.0, or 0.5 mg/kg Administration: Injection, daily for 30 days Result:When the mice were injected with 5 mg/kg ZZW-115, the tumors stopped growing a few days after treatment and their size decreased progressively, almost disappearing at the end of the treatment.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    801991-87-7
  • Formula Weight
    464.59
  • Molecular Formula
    C24H31F3N4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(CCN1CCN(CCN(C)C)CC1)N2C=3C(SC=4C2=CC=CC4)=CC=C(C(F)(F)F)C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Santofimia-Casta?o P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28.?
molnova catalog
related products
  • Ameltolide

    Ameltolide is an anticonvulsant agent. It has been shown to be effective at inhibiting seizures in animal models.

  • VULM 1457

    VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes.

  • Dalbavancin Impurity

    Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.